ArticleCardiology research and practice2012
The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease.
Article in Cardiology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 79 citations in OpenAlex.
- Trimetazidine Improves the Outcome of EECP Therapy in Patients with Refractory Angina Pectoris.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Trial
- Inflammation in acute coronary syndrome: Expression of TLR2 mRNA is increased in platelets of patients with ACS.PloS one · 2019Trial
- Peptide 19-2.5 inhibits heparan sulfate-triggered inflammation in murine cardiomyocytes stimulated with human sepsis serum.PloS one · 2015Trial
- Prognostic Value of Conventional and Modified Naples Scores for In-Hospital Mortality in Patients with Non-ST-Elevation Acute Coronary Syndrome.Medicina (Kaunas, Lithuania) · 2026Article
- Causal Relationship Between Psoriatic Arthritis and Coronary Heart Disease: A Mendelian Randomization and Bioinformatics Analysis.Psoriasis (Auckland, N.Z.) · 2026Article
- Risk Factors for Immune Checkpoint Inhibitor-Related Myocarditis: An Integrative Review.Journal of the advanced practitioner in oncology · 2024Review
- CD8Frontiers in immunology · 2024Article
- Commencement of Atorvastatin and Ezetimibe Immediately in Patients Presenting with Acute Coronary Syndrome.European cardiology · 2024Review
- Immune-inflammatory biomarkers for the occurrence of MACE in patients with myocardial infarction with non-obstructive coronary arteries.Frontiers in cardiovascular medicine · 2024Article
- The Impacts of Animal-Based Diets in Cardiovascular Disease Development: A Cellular and Physiological Overview.Journal of cardiovascular development and disease · 2023Review
- Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity.Molecules (Basel, Switzerland) · 2023Review
- The Role of Punicalagin and Its Metabolites in Atherosclerosis and Risk Factors Associated with the Disease.International journal of molecular sciences · 2023Review
- Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-Related Metabolic Diseases.Biomolecules · 2023Review
- Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence.International journal of molecular sciences · 2022Article
- Interleukin Receptor Associated Kinase 1 Signaling and Its Association with Cardiovascular Diseases.Reviews in cardiovascular medicine · 2022Review
- A High-Cholesterol Diet Increases Toll-like Receptors and Other Harmful Factors in the Rabbit Myocardium: The Beneficial Effect of Statins.Current issues in molecular biology · 2021Article
- Heat shock protein 60 and cardiovascular diseases: An intricate love-hate story.Medicinal research reviews · 2021Review
- An Overview of Glycosylation and its Impact on Cardiovascular Health and Disease.Frontiers in molecular biosciences · 2021Review
- Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications.Journal of immunology research · 2020Review
- Toll-like receptor 4 polymorphisms in Saudi population with cardiovascular diseases.Molecular genetics & genomic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is a complex disorder involving multiple pathophysiological processes, several of which involve activation of toll-like receptors (TLRs) of the innate immune system. As sentinels of innate immunity TLRs are nonclonally germline-encoded molecular pattern recognition receptors that recognize exogenous as well as tissue-derived molecular dangers signals promoting inflammation. In addition to their expression in immune cells, TLRs are found in other tissues and cell types including cardiomyocytes, endothelial and vascular smooth muscle cells. TLRs are differentially regulated in various cell types by several cardiovascular risk factors such as hypercholesterolemia, hyperlipidemia, and hyperglycemia and may represent a key mechanism linking chronic inflammation, cardiovascular disease progression, and activation of the immune system. Modulation of TLR signaling by specific TLR agonists or antagonists, alone or in combination, may be a useful therapeutic approach to treat various cardiovascular inflammatory conditions such as atherosclerosis, peripheral arterial disease, secondary microvascular complications of diabetes, autoimmune disease, and ischemia reperfusion injury. In this paper we discuss recent developments and current evidence for the role of TLR in cardiovascular disease as well as the therapeutic potential of various compounds on inhibition of TLR-mediated inflammatory responses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.